Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study
Keywords: ناخنک زدن; Lung cancer; nonsquamous; MET inhibitor; tivantinib; erlotinib; EGFR;